Market Expansion Meridian operates in over 70 countries and has strong positions in gastrointestinal, upper respiratory infections, and blood lead level testing, indicating opportunities to expand diagnostic kits and reagents into new regions and hospital networks through existing global distribution.

Strategic Partnerships Recent collaboration with 4Bases SA to broaden KaryoSolver deployment suggests a pathway to co-sell or co-develop cytogenetics solutions, opening doors for integrators, reference labs, and research centers needing advanced cytogenomics platforms.

NGS Enablement Launch of Lyophilized NGS Enzymatic DNA Fragmentation Kit positions Meridian to target next-generation sequencing laboratories with stable, ready-to-use reagents, offering recurring revenue through consumables and kit upgrades.

Enzyme Stabilization The focus on enzyme stabilization for diagnostics enhances product reliability and shelf life, presenting upsell opportunities for end users seeking robust assays in point-of-care, low-resource, or remote settings.

Regulatory & FDA Footprint Prior FDA clearances and ongoing diagnostics initiatives indicate a track record with regulatory bodies, enabling sales teams to target hospitals and reference labs seeking compliant, field-ready diagnostic solutions and faster time-to-market for new tests.